AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
89,900
AstraZeneca PLC News & Analysis
funds
UK assets may hold renewed appeal despite Brexit blowout
With a General Election slated for December and Brexit postponed until 2020, investors should consider how their portfolios are positioned for more months of uncertainty.
stocks
CSL remains favourite, but biotech field broadening
The biotech giant has jumped 22pc a year for the past decade but new players are emerging.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,410.70 | 94.00 | 1.13% |
| CAC 40 | 7,274.48 | 19.89 | -0.27% |
| DAX 40 | 19,884.75 | 85.11 | -0.43% |
| Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
| FTSE 100 | 8,084.61 | 20.71 | -0.26% |
| HKSE | 19,778.37 | 57.67 | 0.29% |
| NASDAQ | 19,572.60 | 199.83 | 1.03% |
| Nikkei 225 | 39,033.16 | 331.26 | 0.86% |
| NZX 50 Index | 12,912.94 | 8.83 | 0.07% |
| S&P 500 | 5,930.85 | 63.77 | 1.09% |
| S&P/ASX 200 | 8,159.70 | 92.70 | 1.15% |
| SSE Composite Index | 3,363.21 | 4.86 | -0.14% |